Pulmonary arterial hypertension (PAH) can be a challenging condition for children, often requiring specialized treatment. A recent systematic review looked at the effectiveness and safety of parenteral treprostinil, a medication that could make a difference for these young patients. The review included 32 studies with 766 children treated with parenteral prostacyclins, and specifically focused on 143 children who had not previously received treprostinil. While there were no randomized controlled trials, the data clearly showed that parenteral treprostinil offers a treatment benefit for children with PAH. The findings were supported by statistically significant results in the meta-analysis, indicating that this medication is not only effective but also safe. For families dealing with pediatric PAH, this information is crucial, as it highlights a potential treatment that could improve their child's health and quality of life.
Parenteral Treprostinil Shows Efficacy in Pediatric PAH, Meta-Analysis ConfirmsCan parenteral treprostinil help kids with pulmonary arterial hypertension?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider parenteral treprostinil for pediatric PAH due to demonstrated efficacy and safety.
A systematic review and meta-analysis evaluated the efficacy and safety of parenteral treprostinil in pediatric pulmonary arterial hypertension (PAH). The study included a comprehensive literature search from January 2000 to April 2024, identifying 32 studies with 766 pediatric PAH patients treated with parenteral prostacyclins, of which 649 received treprostinil. The meta-analysis focused on five publications encompassing 143 treprostinil-naïve patients. Despite the absence of randomized controlled trials, the meta-analysis revealed statistically significant improvements in PAH-relevant efficacy endpoints, indicating a clear treatment benefit of parenteral treprostinil. The findings suggest that, based on the available data, parenteral treprostinil is both effective and safe for treating pediatric PAH. However, the reliance on cohort studies and retrospective data highlights the need for further research to strengthen the evidence base.
What this means for you:
Parenteral treprostinil is effective and safe for treating pediatric pulmonary arterial hypertension. More on Pulmonary Arterial Hypertension
Vascular smooth muscle cell immune interactions drive remodeling across cardiovascular diseases
How blood vessel cells drive heart disease and high blood pressure
This narrative review synthesizes mechanisms of VSMC-immune interactions in atherosclerosis, hypertension, aortic aneurysms, and arteritis. …
A new review reveals how blood vessel cells change in heart disease, high blood pressure, and more.
Mechanical shear stress influences endothelial RNA methylation in atherosclerosis and pulmonary arterial hypertension
Mechanical forces on blood vessel cells may change how they repair themselves
This narrative review examines the interplay between hemodynamic shear stress and epitranscriptomic mechanisms in endothelial cells. The aut…
New review suggests blood flow forces might alter how RNA works in cells lining our vessels, potentially affecting heart and lung health.
Narrative review highlights limited data on connective tissue disease-associated PAH in Han Chinese populations
New data reveals how lung pressure risks differ for Chinese patients with connective tissue disease
This narrative review examines connective tissue disease-associated pulmonary arterial hypertension, specifically systemic sclerosis-associa…
A new review shows that lung pressure risks for Chinese patients with connective tissue disease differ from Western populations and require …
Systematic review of immunosuppression for SLE-associated intestinal pseudo-obstruction
SLE Can Shut Down the Gut — But It Might Be Reversible
This review synthesized 43 cases of SLE-associated intestinal pseudo-obstruction.
Lupus can paralyze the gut without a blockage, but early treatment with immunosuppressives often reverses this dangerous complication.
View Original Abstract ↓
BACKGROUND: Paediatric pulmonary arterial hypertension (PAH) shares commonalities with adult disease but is essentially different regarding complexity and is usually more challenging to treat. Current treatment recommendations are based on expert opinion, small-scale paediatric studies and knowledge and consolidated guidelines for adults. Parenteral prostacyclins are recommended for high-risk patients but evidence is limited to cohort studies and retrospective data evaluations. The aim of this article was to summarise the available evidence on the efficacy and safety of parenteral treprostinil for paediatric PAH through a systematic review and to evaluate selected efficacy end-points through meta-analysis.
METHOD: A systematic literature search (January 2000-April 2024) was conducted in PubMed, Google Scholar and clinical trial registries. Eligible studies included those reporting long-term outcomes of parenteral treprostinil in children with PAH. Moreover, a meta-analysis of selected efficacy end-points was performed based on published results from studies meeting predefined criteria.
RESULTS: 32 studies encompassing 766 paediatric PAH patients treated with parenteral prostacyclins were identified; 649 patients received treprostinil. The meta-analysis was based on five publications including a total of 143 treprostinil-naïve patients. Despite the lack of randomised controlled trials, available data clearly indicate a treatment benefit of parenteral treprostinil in paediatric PAH. Literature data are supported by statistically significant results in the meta-analysis for PAH-relevant efficacy end-points.
CONCLUSION: Based on currently available published data, parenteral treprostinil is effective and safe in the treatment of paediatric PAH.
High-Dose Vitamin D and Low-Dose Vitamin A May Reduce Bronchopulmonary Dysplasia in Preterm Infants
High-Dose Vitamin D May Reduce BPD in Preterm Infants
Related in Pediatrics
Congenital cytomegalovirus is associated with a 10-fold increased risk of vestibular changes in children
Children with congenital cytomegalovirus face higher risk of balance issues
This meta-analysis of 8 observational studies examined the association between congenital cytomegalovirus (cCMV) and vestibular outcomes in …
Children born with a specific virus may face much higher risks for inner ear and balance problems, though more research is needed to confirm…
Ambulatory hypertension in pediatric chronic kidney disease patients increases risk of left ventricular hypertrophy
High Blood Pressure Linked to Heart Changes in Children
This meta-analysis of 51 studies involving 6509 children with chronic kidney disease found that ambulatory hypertension is associated with i…
New data shows a strong link between high blood pressure and heart muscle thickening in children with chronic kidney disease.
Early enteral feeding reduces hospital stay by 3.53 days and speeds time to full feeds
Early feeding helps children recover faster after intestinal surgery
This meta-analysis of randomized controlled trials involving 704 pediatric patients found that early enteral feeding (within 48 hours) signi…
Starting tube feedings within 48 hours of intestinal surgery can help children reach full feeds faster and spend less time in the hospital.
NICU noise levels frequently exceed recommended limits and primarily originate from alarms and respiratory devices
NICU noise levels often exceed safety limits for preterm infants
This systematic review of 113 studies identifies alarm systems and respiratory support as primary sources of high-level noise in NICUs. Whil…
Most neonatal intensive care units have noise levels much higher than recommended, especially from alarms and breathing equipment.
From Other Specialties
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…
HIFU combined with ethanol ablation or GnRH-a improves intraoperative outcomes for adenomyosis treatment
HIFU Combined With Medication Shows Better Results for Adenomyosis
This network meta-analysis of 1,685 patients evaluated HIFU combined with various medications compared to HIFU alone for adenomyosis. The an…
Combining high-intensity focused ultrasound (HIFU) with specific medications may improve treatment outcomes for people with adenomyosis.
Risk-optimized use of Janus kinase inhibitors in Japanese patients with rheumatoid arthritis depends on comorbidities
New evidence helps doctors choose safer arthritis treatments for seniors
This narrative review examines the safety and risk profile of Janus kinase inhibitors (JAKi) for rheumatoid arthritis specifically within th…
Doctors are moving toward personalized plans for rheumatoid arthritis, focusing on a patient's specific health risks rather than just their …